ReportWire

Tag: blood clots

  • Deion Sanders will undergo a procedure related to blood clots, plans to coach Colorado this weekend

    [ad_1]

    Colorado coach Deion Sanders will undergo a procedure later Tuesday that’s related to his blood clots, with the hope of being back at practice the next day and on the sideline this weekend against Iowa State.The surgery is called an aspiration thrombectomy, which involves the left popliteal — located behind the knee — and tibial arteries. Sanders said it may take several hours.He gave the medical update at the end of his weekly news conference, saying, “I cannot wait to get past this hurdle.” He added it’s hereditary and “has nothing to do with me working at the level I’m trying to compete at.”The 58-year-old coach was in pain during a 35-21 loss at TCU last Saturday, alternating between sitting and limping along the sideline with his leg throbbing. He didn’t wear a shoe on his left foot in the second half and after the game said he was “hurting like crazy.””I’m going to be all right,” said Sanders, whose Buffaloes (2-4, 0-3 Big 12) host No. 22 Iowa State (5-1, 2-1) on Saturday. “Prayerfully, I’ll be right back tomorrow because I don’t miss practice. I don’t plan on doing such.”Sanders dealt with blood clot issues while at Jackson State in 2021, with doctors amputating two of the toes on his left foot. He also skipped a Pac-12 media day session in 2023 following a procedure to remove a blood clot from his right leg and another to straighten toes on his left foot.On Tuesday, his good friend and longtime NFL cornerback Adam “Pacman” Jones attended the media session as a show of support. Sanders appreciates all the texts and phone calls from people expressing their concern over his health.”I’ve got a lot of well-wishes, of people talking about: ‘You need to slow down. You need to take a break,’” Sanders said. “There’s nothing that I could’ve done to stop what’s transpiring. Nothing that I could’ve taken or something that I’m just not abiding by. It is what it is.”Sanders spent time away from the team over the summer after being diagnosed with an aggressive form of bladder cancer. He revealed details of his treatment, which involved doctors reconstructing a section of his intestine to function as a bladder. He frequently needs to use the restroom, so the school introduced a portable sideline bathroom for him during games that’s sponsored by Depend underwear.”I trust God with all my heart and all my soul and all my mind,” Sanders said Tuesday. “I’m going to go in there (surgery), and I’m going to get some of the best sleep in the world for, I think, four hours, the surgery is going to be.”I’ve never been high a day in my life. I’ve never drank, smoked or anything. But when I get those surgeries, I am there on time.”The Buffaloes are 15-16 since Sanders took over as their coach leading into the 2023 season. They’re trying to get on track this season as they replace quarterback Shedeur Sanders and Heisman Trophy winner Travis Hunter.They’ve lost two games in a row.”The reason I’m still excited about this team that just finished practicing is because I don’t feel like we’ve gotten our butt kicked,” Sanders said. “I feel like we’ve just wrapped it up and given (games) to them. That’s frustrating. But also there’s hope in that. That we see where we’re messing up at, we see where the faults are and we’ve got to fix that. So there’s truly optimism.”I’m not saying we’re a great football team, but we’re not a bad football team. We’re better than we’re playing.”

    Colorado coach Deion Sanders will undergo a procedure later Tuesday that’s related to his blood clots, with the hope of being back at practice the next day and on the sideline this weekend against Iowa State.

    The surgery is called an aspiration thrombectomy, which involves the left popliteal — located behind the knee — and tibial arteries. Sanders said it may take several hours.

    He gave the medical update at the end of his weekly news conference, saying, “I cannot wait to get past this hurdle.” He added it’s hereditary and “has nothing to do with me working at the level I’m trying to compete at.”

    The 58-year-old coach was in pain during a 35-21 loss at TCU last Saturday, alternating between sitting and limping along the sideline with his leg throbbing. He didn’t wear a shoe on his left foot in the second half and after the game said he was “hurting like crazy.”

    “I’m going to be all right,” said Sanders, whose Buffaloes (2-4, 0-3 Big 12) host No. 22 Iowa State (5-1, 2-1) on Saturday. “Prayerfully, I’ll be right back tomorrow because I don’t miss practice. I don’t plan on doing such.”

    Sanders dealt with blood clot issues while at Jackson State in 2021, with doctors amputating two of the toes on his left foot. He also skipped a Pac-12 media day session in 2023 following a procedure to remove a blood clot from his right leg and another to straighten toes on his left foot.

    On Tuesday, his good friend and longtime NFL cornerback Adam “Pacman” Jones attended the media session as a show of support. Sanders appreciates all the texts and phone calls from people expressing their concern over his health.

    “I’ve got a lot of well-wishes, of people talking about: ‘You need to slow down. You need to take a break,’” Sanders said. “There’s nothing that I could’ve done to stop what’s transpiring. Nothing that I could’ve taken or something that I’m just not abiding by. It is what it is.”

    Sanders spent time away from the team over the summer after being diagnosed with an aggressive form of bladder cancer. He revealed details of his treatment, which involved doctors reconstructing a section of his intestine to function as a bladder. He frequently needs to use the restroom, so the school introduced a portable sideline bathroom for him during games that’s sponsored by Depend underwear.

    “I trust God with all my heart and all my soul and all my mind,” Sanders said Tuesday. “I’m going to go in there (surgery), and I’m going to get some of the best sleep in the world for, I think, four hours, the surgery is going to be.

    “I’ve never been high a day in my life. I’ve never drank, smoked or anything. But when I get those surgeries, I am there on time.”

    The Buffaloes are 15-16 since Sanders took over as their coach leading into the 2023 season. They’re trying to get on track this season as they replace quarterback Shedeur Sanders and Heisman Trophy winner Travis Hunter.

    They’ve lost two games in a row.

    “The reason I’m still excited about this team that just finished practicing is because I don’t feel like we’ve gotten our butt kicked,” Sanders said. “I feel like we’ve just wrapped it up and given (games) to them. That’s frustrating. But also there’s hope in that. That we see where we’re messing up at, we see where the faults are and we’ve got to fix that. So there’s truly optimism.

    “I’m not saying we’re a great football team, but we’re not a bad football team. We’re better than we’re playing.”

    [ad_2]

    Source link

  • Deion Sanders to undergo surgery amid ongoing health issues

    [ad_1]

    BOULDER, Colo. — Deion Sanders will undergo a four-hour surgical procedure on Tuesday at UCHealth amid ongoing health issues, including blood clot concerns.

    The 58-year-old Colorado coach told reporters Sunday that he believes he has more blood clots in his leg, and he had a doctor’s appointment Monday to see about the issue.

    “And I trust God with all my heart and all my soul and all my mind, so I’m going to go in there and I’m going to get some of the best sleep in the world for, I think, four hours, the surgery’s going to be,” Sanders said Tuesday during his weekly press conference.

    The surgery is called an aspiration thrombectomy, which involves the left popliteal — located behind the knee — and tibial arteries.

    Sanders, who appeared to be in good spirits Tuesday, said he expects to be back at practice Wednesday. He said the amount of time he’s putting into coaching is not impacting his health.

    The Pro Football Hall of Fame player spent time away from the Buffaloes (2-4, 0-3 Big 12) this summer as he went through treatment for bladder cancer.

    His doctor said before the season that he had been cured of that. It was also revealed that a section of Sanders’ intestine was reconstructed to function as a bladder.

    Sanders has struggled with his left foot since having two toes amputated in 2021 because of blood clot issues while at Jackson State.

    He also missed Pac-12 media day in 2023, his first year at Colorado, after a procedure to remove a blood clot from his right leg and another to straighten toes on his left foot.

    The Associated Press contributed to this report

    Deion Sanders weekly press conference

    Coloradans making a difference | Denver7 featured videos


    Denver7 is committed to making a difference in our community by standing up for what’s right, listening, lending a helping hand and following through on promises. See that work in action, in the videos above.

    [ad_2]

    Robert Garrison

    Source link

  • Doctors Suddenly Got Way Better at Treating Eczema

    Doctors Suddenly Got Way Better at Treating Eczema

    [ad_1]

    Up until a few years ago, Heather Sullivan’s 14-year-old son, Sawyer, had struggled with eczema his entire life. When he was just a baby, most of his body would be covered in intensely itchy rashes that bled and oozed when he couldn’t help but scratch. His family tried steroid creams, wet wraps, bleach baths, and all of the lotions. They tore up their carpet and replaced their sheetrock in hopes of eliminating triggers. At 15 months, he went on cyclosporine, a powerful immunosuppressant usually given to organ-transplant patients. It cleared him up, but the drug comes with potentially dangerous side effects over time. Doctors, Sullivan recalls, were “just appalled that my child would be on this amount of medicine at this age”—but his eczema came roaring back as soon as he went off it.

    When a new eczema drug called Dupixent finally became available to Sawyer a few years ago, his turnaround was fast and dramatic. Within a week, his itchiness and redness started calming down. He felt and looked better. The condition that had dominated their lives began to fade into the background.

    Doctors who treat severe eczema now speak of pre- and post-Dupixent eras: “It changed the landscape of having eczema forever,” says Brett King, a dermatologist at Yale. Today, a half dozen novel treatments are available for the skin condition, all of which work by quieting the same biological pathway in eczema; dozens more are in clinical trials. Unlike older drugs, these new ones are precisely targeted and in many cases startlingly effective.

    Eczema, also known as atopic dermatitis, is characterized by red, itchy, and inflamed skin. It’s a very common condition, estimated to affect 10 percent of Americans. Of those, a large minority suffer from moderate to severe eczema that seeps into everyday life. “Just imagine scratching endlessly,” King says. “You wake up from sleep scratching. Your sheets are bloody in the morning.” The most basic eczema advice is to moisturize, and moisturize often, to protect the barrier of the skin. But scientists now know that eczema’s cause is not in the skin alone. Many patients also have “an over-reactive or overzealous immune system,” says Dawn Davis, a dermatologist at the Mayo Clinic. Their immune cells release chemicals that irritate nerves, causing itch, and even degrade the skin itself.

    Topical steroids, such as over-the-counter hydrocortisone cream, can tamp down the immune reaction that flares in eczema. If these fail, doctors have resorted to more powerful oral steroids, such as prednisone, or other oral immunosuppressants, such as the aforementioned cyclosporine. The drugs can calm eczema, but because they suppress the overall immune system, they also do much more. Prednisone, for example, makes you more prone to infections as well as bone fractures, high blood pressure, and glaucoma when taken in the long term. Of course, for many people, eczema is a chronic condition that requires long-term treatment. “Prednisone is kind of like carpet bombing,” says Peter Lio, a dermatologist at Northwestern University. It blasts eczema away, but at a cost.

    In contrast, the newer drugs, Lio says, are more like shotguns that target specific parts of the immune system—with less collateral damage. They fall into two broad classes. Monoclonal antibodies, such as Dupixent, intercept the immune-signaling molecules that trigger itch and skin inflammation. And then JAK inhibitors, which include pills such as Rinvoq and the topical cream Opzelura, scramble the signal after cells have received it. The development of these drugs came after years of research zeroed in on some of the key immune molecules dysregulated in eczema. But serendipity played a role too: The first such drugs were originally developed for other conditions, such as rheumatoid arthritis—only to be repurposed when researchers realized that they targeted the very pathways involved in eczema. The breakthroughs in eczema treatment, in fact, are part of a broader revolution in treating inflammatory disorders; both classes of new drugs are now used to tune the immune system in a whole host of different conditions.

    The monoclonal antibodies and oral JAK inhibitors may have their own serious side effects, such as blood clots, which, Lio says, give some doctors unfamiliar with the new drugs—especially the latter type—pause. But the traditional drugs are not great either. “I’m frustrated that a lot of clinicians are very cavalier about prednisone and cyclosporine … They’re like, ‘Oh, they’re our old friends,’” he told me. “Then they get nervous about JAK inhibitors.” In his mind, the new drugs are simply the better option in terms of safety and efficacy.

    Jonathan Silverberg, a dermatologist at George Washington University who specializes in eczema, says he now rarely uses the old oral steroids and immunosuppressants. When he does revert to them, it’s not for medical reasons: He ends up prescribing older (that is, generic and therefore cheaper) drugs for uninsured patients who can’t afford the new ones, or for patients who have insurance but are nevertheless denied coverage. “Insurance says, ‘Can it be fixed with a $10 medicine? Or does it really need the $1,000 tube?’” King told me. Getting patients these newer drugs can mean a lot of time fighting with insurance.

    For now, these drugs have most dramatically improved the lives of patients with moderate to severe eczema—at least those patients who can access them. But doctors told me that topical JAK inhibitors, which are safer than the oral version, could one day be first-line treatments for mild eczema as well. “In a perfect world, I would love it if I never had to prescribe a topical steroid again,” Silverberg said, citing the side effects that come with long-term use. Topical steroids can thin the skin, causing stretch marks, fragility, and poor healing. But at the moment, steroids are also cheap and easily available. They’re not going anywhere as long as the new treatments still come with hefty price tags.

    [ad_2]

    Sarah Zhang

    Source link

  • We’ve Had a Cheaper, More Potent Ozempic Alternative for Decades

    We’ve Had a Cheaper, More Potent Ozempic Alternative for Decades

    [ad_1]

    The Ozempic craze shows no signs of slowing. Demand for the drug, popularly used for weight loss, is so monumental that it is already changing the diet industry and spurring a “marketing bonanza” among the dozens of telehealth start-ups that now prescribe it. A highly public ad campaign from one start-up, Ro, banks on the drug’s simple premise: “A weekly shot to lose weight.”

    Never before has a weight-loss treatment been hyped this way and been able to deliver on its promise. Ozempic itself is technically a diabetes drug, but its active ingredient, semaglutide, has been approved by the FDA for weight loss under the brand name Wegovy, and can reduce a person’s body weight by up to 20 percent through a weekly injection. An even more powerful drug, known as tirzepatide, or Mounjaro, may soon be approved for weight loss, and a host of new medications are coming down the pipeline. All signs suggest that America is on the verge of a weight-loss revolution.

    But for people with obesity, semaglutide isn’t even the most effective weight-loss treatment around—not even close. Bariatric surgery, which has existed for many decades, is still significantly more potent. This class of procedures, which, broadly speaking, reconfigure the digestive system so people feel less hungry and more full, is considered to be the “gold standard” for treating obesity, Holly Lofton, an obesity-medicine physician at NYU, told me. Most people experience weight loss of 50 percent and, with one procedure, up to 80 percent, according to the Cleveland Clinic.

    Despite the impressive abilities of the new crop of weight-loss drugs—and bold assertions that such drugs could someday replace surgery outright—several doctors told me that surgery will likely continue to be the top-line treatment for obesity, even as the medications improve. People may seek out treatment with the new drugs because they’re so popular, but “long term, there will be an increase in surgery,” Shauna Levy, a professor specializing in bariatric surgery at Tulane University School of Medicine, told me. The new drugs, however potent, may be less a revolutionary fix for obesity and more a powerful tool for treating it—one of many that already exist.


    Unlike semaglutide, bariatric surgery, first introduced in the 1950s, took several decades to become accepted by the medical community. Initial attempts made people so sick that, at times, the surgery had to be reversed. The term bariatric surgery refers to several different procedures that reshape the gastrointestinal tract so that it absorbs fewer nutrients, holds less food, or both. These days, the most commonly performed surgery is called a Roux-en-Y, which shrinks the stomach to the size of a walnut—so people need less food to feel satisfied—and then reconnects it to the small intestine in a Y shape, rather than linearly. This gastric bypass lets food circumvent most of the stomach, leaving fewer opportunities for the body to harvest nutrients. In another common procedure, surgeons sculpt the stomach into a banana-size “sleeve” and toss the rest; another common type involves rerouting the intestines in a way that minimizes the area where calories can be absorbed.

    But bariatric surgery does more than shrink gastrointestinal real estate. It exerts a less visible but equally powerful effect on the many different hormones that control hunger. Some procedures remove the part of the gut that produces the “hunger hormone,” ghrelin, while the rerouting of food through a Roux-en-Y ramps up the release of “incretin” hormones that create the feeling of fullness after eating.

    In a sense, the new weight-loss drugs are essentially trying to re-create the effects of bariatric surgery: The success of these drugs is due to their ability to mimic the incretin hormones and get people to feel satisfied with less food. Semaglutide masquerades as the hormone GLP-1, whereas Mounjaro poses as both GLP-1 and GIP. But these are just two hormones; bariatric surgery “touches on multiple different hormones and different pathways” and, as such, is “more comprehensive,” Levy said. In one study, Mounjaro, considered the most powerful of the current crop of medications, led to 20 percent or more weight loss in 57 percent of people who took the highest dose—an impressive feat, but still a far cry from what is possible with surgery. Similarly, Ozempic and Mounjaro, both technically diabetes drugs, have powerful effects on blood-sugar levels over time, but many surgery patients “leave the hospital already in remission from their diabetes,” Levy said.

    In addition to sheer potency, surgery is also much more affordable than these weight-loss drugs. Unlike the drugs, bariatric surgery is covered by Medicare if the patient meets certain criteria, including having a BMI equal to or greater than 35 and at least one comorbidity related to obesity. Many private insurers cover it too, albeit to varying degrees. Out of pocket, surgery costs $15,000 to $25,000—not cheap, but still cheaper than shelling out more than $1,000 a month indefinitely. “The patient must understand that they have to continue taking medication forever,” Lofton said. People who stop taking semaglutide generally regain the weight they lost. Lofton told me about one patient who had to forgo rent just to pay for the drugs: Factoring in insurance, “you can pay for three months of medicine and then have surgery at the same price.”

    Neither treatment, of course, is without its potential downsides. Semaglutide can cause temporary but nasty side effects such as nausea, vomiting, and diarrhea—and though it is considered safe for treating obesity, long-term data on this usage span just two years. Because many surgeries are done laparoscopically—using only tiny incisions—mortality is vanishingly low, and many patients go home after two or three days; full recovery usually takes four to six weeks. In the long term, complications such as hernias, gallstones, and low blood sugar can develop.

    But there’s a reason bariatric surgery has not led to a weight-loss revolution of the kind that now gets associated with semaglutide. Despite its dramatic effects, and obesity’s prevalence across America, only 1 percent of people eligible for surgery actually get it. People hesitate for many reasons, medical and otherwise, but the most pervasive issue is a lack of awareness that surgery is even a safe or realistic option for weight loss. Bariatric surgery is plagued by stigma even within the medical community: In the 1990s, it was dismissed as a “barbaric” way to address an issue that, many believed, could be treated with diet and exercise. “There are a lot of primary-care doctors who are not talking enough about surgery” because they were trained with that old mindset, Levy said. ​​It doesn’t help that bariatric surgery hasn’t exactly been a media sensation, with few high-profile patient advocates beyond Al Roker and Mariah Carey. In contrast, stories of celebrities on weight-loss drugs abound. Unlike surgery, semaglutide has the potential to be taken recreationally.


    The advantages that surgery has over weight-loss drugs may change as the drugs become more potent and eventually cheaper. But for now, semaglutide won’t dramatically shift the way obesity is treated, doctors told me—in fact, these new drugs may act as a conduit to surgery itself. Levy predicts that their sheer popularity will trigger a brief dip in the bariatric-surgery rate, but as price remains an issue, and people with obesity are unable to reach their weight-loss goals on the drugs alone, “they may start opening their mind to surgery.”

    Certainly, in some patients, weight-loss drugs alone could lead to lasting weight loss. And they can benefit those who are overweight but don’t qualify for surgery. But more widely, these drugs will likely be used in tandem with bariatric surgery to produce more dramatic, longer-lasting results, experts told me. “I don’t see this as an either/or,” Fatima Cody Stanford, an obesity-medicine physician at Massachusetts General Hospital and Harvard Medical School, told me. “I see it as surgery plus medicine.”

    Drugs can help fill in any gaps that surgery leaves behind. Weight can rebound after a procedure, because the body has a way of rebalancing itself; hormones that were tamped down due to bariatric surgery, Stanford said, can “start to reemerge with a vengeance.” About a fifth of people, and perhaps even more, regain a significant amount of weight—15 percent or more—two to five years after surgery. All of the doctors I spoke with said that medication could be a powerful tool to prevent post-surgery weight rebounds—though to keep that weight off, the medication would still have to be taken in perpetuity. Stanford estimated that more than 90 percent of her patients are on weight-loss drugs after surgery—and not necessarily semaglutide; older medications often suffice. Drugs could also be used to help people prepare for surgery, Lofton said. Some doctors encourage patients to lose weight beforehand to decrease the risk of complications such as blood clots, heart attack, and infection.

    Despite the hype, weight-loss drugs were never a perfect treatment for obesity. Neither is bariatric surgery, for that matter. “It is not a cure,” Lofton told me. A cure, she explained, would ensure that hunger doesn’t return and that fat cells don’t get bigger, a hallmark of obesity: “We have nothing that does that”—not even more potent next-gen drugs will provide a permanent fix. But the effect of combining surgery and medication could come close, she said.

    That no cure for obesity exists is evidence of its complexity. All of the experts I spoke with pointed out that obesity has long been misunderstood as a failure of personal will, as laziness or gluttony. That misunderstanding has led to inadequate care: Many people who regain weight after a bariatric procedure are made to feel by their doctors like they “wasted the surgery,” even if human biology is to blame, Stanford said. Ozempic and other weight-loss medications frame obesity as a condition that can be treated with drugs—in other words, a disease. Patients on those medications may realize, “Hey, maybe it’s not just me being lazy this whole time—maybe there is science to it and an actual disease here,” said Levy. Collectively understanding obesity as an illness that exists alongside heart disease and cancer—diseases routinely treated with medication and surgery—instead of as a matter of personal inadequacy will have far more profound impacts on people with obesity than any drug alone.

    [ad_2]

    Yasmin Tayag

    Source link

  • Hailey Bieber Reflects On Her Mini-Stroke 1 Year Later

    Hailey Bieber Reflects On Her Mini-Stroke 1 Year Later

    [ad_1]

    Hailey Bieber recently reflected on suffering a mini-stroke last year.

    On Friday, the model posted on her Instagram story a video she created in April 2022 where she discussed having experienced a transient ischemic attack, often called a mini-stroke, the previous month. The incident led to her diagnosis of patent foramen ovale, which is when “a hole in the heart didn’t close the way it should after birth,” as the Mayo Clinic describes it.

    “Can’t believe it’s been 1 year since I suffered a mini stroke that led to my PFO diagnosis,” Bieber wrote in a text overlay on her post Friday. “Given that it’s the 1 year mark from such a life changing event, I wanted to share all the information I’ve learned about PFO and share resources to donate.”

    In the 2022 video describing her health condition, Bieber said that doctors told her she had a small blood clot that traveled into her heart, then through the hole in her heart, and eventually to her brain.

    Bieber said she underwent a procedure to address the PFO, and that it went “very smoothly.”

    In January, Bieber said the health scare had since caused her “a lot of anxiety.”

    “I struggled with a little bit of PTSD of just, like, the fear of maybe it was gonna happen again,” she said during an appearance on the “Run-Through with Vogue” podcast.

    Justin and Hailey Bieber at the 64th Annual Grammy Awards on April 3, 2022, in Las Vegas.

    Kevin Mazur via Getty Images

    The model first shared the news that she had suffered a blood clot on Instagram, just days after it happened.

    She said at the time that the experience was one of the “scariest moments” she’d been through.

    Singer Justin Bieber addressed his wife’s health issues at a concert shortly after her mini-stroke, telling the crowd that Hailey was “strong.”

    “It’s been scary … It’s been really scary,” he said. “But I know for a fact that God has her in the palm of his hands.”

    [ad_2]

    Source link

  • Tiny, Menacing Microclots May Explain Long COVID’s Symptoms

    Tiny, Menacing Microclots May Explain Long COVID’s Symptoms

    [ad_1]

    SOURCES:

    Hannah Davis, founding member and researcher, Patient-Led Research Collaborative.

    Etheresia (Resia) Pretorius, PhD, head of department and distinguished research professor, Physiological Sciences Department, Faculty of Science, Stellenbosch University, South Africa.

    Douglas Kell, PhD, research chair in systems biology, Department of Biochemistry, University of Liverpool, U.K.

    Michael VanElzakker, PhD, neuroscientist, Massachusetts General Hospital and Harvard Medical School; co-founder, PolyBio Research Foundation.

    Biochemical Journal: “A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications.”

    Preprint, medRxiv: “Prevalence of amyloid blood clots in COVID-19 plasma.”

    Cardiovascular Diabetology: Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC).”

    Bioanalytical Sciences Group: “Long COVID and the role of fibrin amyloid (fibrinaloid) microclots.”

    U.S. Government Accountability Office: “Science and Tech Spotlight: Long Covid.”

    The Guardian: “Could microclots help explain the mystery of long Covid?”

    Frontiers in Microbiology: “Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms.”

    Nature Microbiology: “Metagenomic compendium of 189,680 DNA viruses from the human gut microbiome.”

    Bioscience Reports: “SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19.”

    Clinical Infectious Diseases: “Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae.”

    YouTube: “The ‘Microclot’ Pathology of Long Covid With Dr Jaco Laubscher,” Gez Medinger:.

    Preprint, Research Square: “Combined triple treatment of fibrin amyloid microclots and platelet pathology in individuals with Long COVID/ Post-Acute Sequelae of COVID-19 (PASC) can resolve their persistent symptoms”

    The BMJ: “Long covid patients travel abroad for expensive and experimental ‘blood washing.’”

    Studies, Surveys and Supplements: “Frequently Asked Questions: Nattokinase, Lumbrokinase & Serrapeptase.”

    [ad_2]

    Source link

  • Tiny, Menacing Microclots May Explain Long COVID’s Symptoms

    Tiny, Menacing Microclots May Explain Long COVID’s Symptoms

    [ad_1]

    Tiny, Menacing Microclots May Explain Long COVID’s Symptoms


    By
    Claire Sibonney
    WebMD Health News


    Dec. 7, 2022 – When Hannah Davis saw the first visual confirmation of long COVID in her blood – a firework-like display of fluorescent green dots against a black background – she was overwhelmed with an odd sense of relief. In early November, she became one of the first U.S. long COVID patients to be tested for microscopic blood clots, catching up to South Africa, Germany, the U.K., and other countries that are already experimenting with related treatments. 


    “It was validating,” says Davis, who excitedly shared the images of her clots on Twitter. “It’s basically the first test specific to long COVID that is promising and scientifically sound and incorporates research from other post-viral illnesses.”



    <blockquote class=”twitter-tweet”><p lang=”en” dir=”ltr”>Big news: I was lucky to get tested for micro blood clots, &amp; I have a lot of them! <a href=”https://twitter.com/hashtag/LongCovid?src=hash&amp;ref_src=twsrc%5Etfw”>#LongCovid</a><br><br>Healthy control blood on the left. Mine on the right. The green is all microclots!<br><br>These clots are likely blocking oxygen from getting around my body &amp; could explain many symptoms. 1/ <a href=”https://t.co/5rtuzN8D8f”>pic.twitter.com/5rtuzN8D8f</a></p>&mdash; Hannah Davis (@ahandvanish) <a href=”https://twitter.com/ahandvanish/status/1592626664131145728?ref_src=twsrc%5Etfw”>November 15, 2022</a></blockquote> <script async src=”https://platform.twitter.com/widgets.js” charset=”utf-8″></script>


    Davis donated her blood at Mount Sinai Hospital in New York City, with a few other founding members of the Patient-Led Research Collaborative, all of whom had been infected in the first wave of the pandemic and are still sick nearly 3 years later. Seeing the pictures of their blood clots, Davis and her fellow patients cried what she called happy tears. Then the reality of having those notorious blood clots sank in.


    Early in the COVID-19 pandemic, emergency room doctors and others treating patients noticed the sickest produced excessive blood clots. The clots clogged kidney dialysis machines, caused strokes, and killed patients long after they left the hospital. Some long COVID researchers have suspected smaller, less obvious blood clots may be causing many of the puzzling symptoms reported by patients who have lasting effects of the virus.


    The theory is that these weird and persistent clots, called microclots, might be blocking delicate blood vessels throughout the body, and stopping oxygen from getting to where it needs to go, causing everything from shortness of breath and organ damage to brain fog and debilitating fatigue. But if all the havoc is being done inside these minuscule clots, regular pathology tests won’t pick it up. A network of specialists is now setting out to see if specialized tests can be accessible and if the clots can be treated.

    [ad_2]

    Source link

  • What Doctors Still Don’t Understand About Long COVID

    What Doctors Still Don’t Understand About Long COVID

    [ad_1]

    As a pulmonary specialist, I spend most of my clinical time in the hospital—which, during pandemic surges, has meant many long days treating critically ill COVID-19 patients in the ICU. But I also work in an outpatient clinic, where I also treat those same sorts of patients after they’re discharged: people who survived weeks-long hospitalizations but have been dealing ever since with lung damage. Such patients often face the same social and economic factors that made them vulnerable to COVID-19 to begin with, and they require attentive care.

    Patients like these undoubtedly suffer what researchers have been calling post-acute sequelae of SARS-CoV-2, or PASC—which, according to one highly publicized recent CDC study, afflicts some 20 percent of COVID-19 survivors ages 18 to 64. Other studies have yielded lower estimates of the condition also called long COVID, and while differences in study methodology account for some of this variability, there’s a more fundamental issue eluding efforts to uncover the one “true” estimate of the likelihood of this condition. Quite simply, long COVID isn’t any one thing.

    The wide spectrum of conditions that fall under the umbrella of long COVID impedes researchers’ ability to interpret estimates of national prevalence based on surveys of symptoms, which conflate different problems with different causes. More importantly, however, an incomplete and constrained perspective on what long COVID is or isn’t limits Americans’ understanding of who is suffering and why, and of what we can do to improve patients’ lives today.

    The cases of long COVID that turn up in news reports, the medical literature, and in the offices of doctors like me fall into a few rough (and sometimes overlapping) categories. The first seems most readily explainable: the combination of organ damage, often profound physical debilitation, and poor mental health inflicted by severe pneumonia and resultant critical illness. This serious long-term COVID-19 complication gets relatively little media attention despite its severity. The coronavirus can cause acute respiratory distress syndrome, the gravest form of pneumonia, which can in turn provoke a spiral of inflammation and injury that can end up taking down virtually every organ. I have seen many such complications in the ICU: failing hearts, collapsed lungs, failed kidneys, brain hemorrhages, limbs cut off from blood flow, and more. More than 7 million COVID-19 hospitalizations occurred in the United States before the Omicron wave, suggesting that millions could be left with damaged lungs or complications of critical illness. Whether these patients’ needs for care and rehabilitation are being adequately (and equitably) met is unclear: Ensuring that they are is an urgent priority.

    Recently, a second category of long COVID has made headlines. It includes the new onset of recognized medical conditions—like heart disease, a stroke, or a blood clot—after a mild COVID-19 infection. It might seem odd that an upper respiratory tract infection could trigger a heart attack. Yet this pattern has been well described after other common respiratory-virus infections, particularly influenza. Similarly, various types of infections can lead to blood clots in the legs, which can travel (dangerously) to the lungs. Respiratory infections are not hermetically sealed from the rest of the body; acute inflammation arising in one location can sometimes have consequences elsewhere.

    But mild COVID-19 is so common that measuring the prevalence of such complications—which also regularly occur in people without COVID-19—can be tricky. Well-controlled investigations are needed to disentangle causation and correlation, particularly because social disadvantage is associated both with COVID exposure and illnesses of basically every organ system. Some such studies, which analyzed giant electronic-health-record databases, have suggested that even mild COVID-19 is at least correlated with a startlingly wide spectrum of seemingly every illness, including diabetes, asthma, and kidney failure; basically every type of heart disease; alcohol-, benzodiazepine-, and opioid-use disorders; and much more.

    To be clear, this research generally suggests that such complications occur far less often after mild COVID-19 cases than severe ones, and the extent to which the coronavirus causes each such complication remains unclear. In other words, we can surmise that at least some of these complications (particularly vascular complications, which have been well-described in many studies) are likely a consequence of COVID-19, but we can’t say with certainty how many. And more importantly, we don’t yet understand why some people with mild COVID recover easily while others go on to experience such complications. However, an estimated 81 percent of Americans have now been infected at least once, so the public-health ramifications are large even if COVID causes only some of the aforementioned recognized diseases, and even if our individual risk of complications after a mild infection is modest. Regardless of cause, patients who do develop any such chronic diseases require attentive, ongoing medical care—a challenge in a nation where 30 million are uninsured and even more underinsured.

    Another category of long COVID is something rather more quotidian, if still very distressing for those experiencing it: respiratory symptoms that last longer than expected after an acute upper-respiratory infection caused by the coronavirus, but that are not associated with lung damage, critical illness, or a new diagnosis like a heart attack or diabetes. Symptoms such as shortness of breath and chest pain are common months after run-of-the-mill pneumonia unconnected to the coronavirus, for instance, while many patients who contract non-COVID-related upper respiratory infections subsequently report a protracted cough or a lingering loss of their sense of smell. That a COVID-related airway infection sometimes has similar consequences only stands to reason.

    However, none of these may be what most people think of when long COVID is invoked. Some may even argue that such syndromes are not, in fact, long COVID at all, even if they cause long-term suffering. “Long Covid is not a condition for which there are currently accepted objective diagnostic tests or biomarkers,” wrote Steven Phillips and Michelle Williams in the New England Journal of Medicine. “It is not blood clots, myocarditis, multisystem inflammatory disease, pneumonia, or any number of well-characterized conditions caused by Covid-19.” Instead, for some the term may invoke a chronic illness—a complex of numerous unexplained, potentially debilitating symptoms—even among those who may barely have felt sick with COVID in the acute phase. Symptoms may vary widely, and include severe fatigue, cognitive issues often described as brain fog, shortness of breath, “internal tremors,” gastrointestinal problems, palpitations, dizziness, and many other issues around the body—all typically following a mild acute respiratory infection. If the other forms of long COVID seem more easily explainable, this type is often characterized as a medical mystery.

    Teasing apart which kind of long COVID a person has is important, both to advance our understanding of the illness and to best care for people. Yet lumping and splitting varieties of long COVID into categories is not easy. A given patient’s case might have features of more than one of the types that I’ve described here. Some patient advocates and researchers have tended to exclude patients in the first category—that is, survivors of protracted critical illness—from their conception of COVID long-haulers. I would argue that, insofar as we define long COVID as lasting damage and symptoms imposed by SARS-CoV-2, the full variety of severe long-term manifestations should be included in its scope. “Clinical phenotyping” studies now under way may eventually help scientists and doctors better understand the needs of different types of patients, but patients in all categories deserve better care today.

    The biological mechanisms by which an acute coronavirus upper respiratory infection might lead to a bewildering range of chronic, burdensome symptoms even in the aftermath of mild infections are debated. Some scientists, for instance, believe that the virus causes an autoimmune disease akin to lupus. Meanwhile, one group of researchers has argued that even a mild respiratory infection from SARS-CoV-2 causes tiny clots to block tiny blood vessels all over the body, depriving tissues of oxygen throughout the body. Still others believe that the coronavirus causes a chronic infection, as such viruses as HIV or hepatitis C do. Meanwhile, some have emphasized the possibility of structural brain damage. While some published studies have provided support for each theory, none has been adequately validated as a central unifying thesis. Each is, however, worth continuing to explore.

    A recently published investigation, conducted at the National Institutes of Health, suggests that clinicians and scientists should consider additional possibilities as potential drivers of symptoms for at least some patients. The researchers found far higher levels of physical symptoms and mental distress among subjects who had had COVID (many with long COVID) than among those who had not. Yet symptoms could not be explained by basically any test results: Researchers found effectively no substantive differences in markers of inflammation or immune activation, in objective neurocognitive testing, or in heart, lung, liver, or kidney function. And yet these patients were suffering from such symptoms as fatigue, shortness of breath, concentration and memory problems, chest pain, and more. Notably, researchers did not identify viral persistence in the bodies of patients reporting troublesome symptoms.

    What this means in practice is that there are some people suffering from long COVID symptoms without evidence of structural damage to the body, autoimmunity, or chronic infection. Psychosocial strain and suffering, moreover, appears common in this population. Even pointing this out is sensitive territory—it leads some people to wrongly suggest that long COVID is less severe or concerning than those suffering from it describe, or even to question the reality of the illness. And, understandably, the invocation of psychosocial factors as potential contributing factors to suffering for some individuals may make patients feel as though they are being second-guessed. The reality, though, is that psychosocial strain is an important driver of physical symptoms and suffering—one that clinicians should treat with empathy. All suffering, after all, is ultimately produced and perceived in one place: our brain.

    Severe depression, for instance, can inflict debilitating and severe physical symptoms of every sort, including crushing fatigue and withering brain fog, and is itself linked to having had COVID-19. And notably, a recent study in JAMA Psychiatry found that pre-infection psychosocial distress—e.g. depression, anxiety, or loneliness—was associated with a 30–50 percent increase in the risk of long COVID among those infected, even after adjustment for various factors. A false separation of brain and body has long plagued medicine, but it does not reflect biological reality: After all, diverse neuropsychiatric processes are associated with numerous “physical” changes, ranging from reduced blood flow to the brain to high (or low) levels of the stress hormone cortisol.

    Illnesses of any cause that result in protracted time off one’s feet can also instigate (likely in conjunction with other factors) reversible cardiovascular deconditioning, wherein the blood volume contracts and the amount of blood ejected by the heart with each squeeze falls—changes that can lead to a racing heart rate or faintness when standing, as decades of studies have shown. Diverse neurological symptoms can also be produced by a glitch in the function rather than the structure of the brain—or what has been described as problems of brain “software” rather than “hardware”—resulting in conditions known as functional neurological disorders. Similar glitches, known as functional respiratory disorders, can disturb our breathing patterns or cause shortness of breath, even when our lungs are structurally normal. My point is not to speculate on some overarching hypothesis to explain all symptoms among all patients with long COVID. The whole point is that there’s unlikely to be just one. And there is still much to learn.

    Research is underway to better understand this spectrum of illnesses, and their causes. But whichever diverse factors might be contributing to patients’ symptoms, we can take steps—both among clinicians and as a society—to improve lives now. Social supports can be as important as medical interventions: For those unable to work, qualification for disability assistance should not depend on a particular lab or lung-function test result. All patients with long-COVID symptoms deserve and require high-quality medical care without onerous cost barriers that may bankrupt them, which further compounds suffering. Universal healthcare is, that is to say, desperately needed to respond to this pandemic and its aftermath.

    Additionally, while no specific long-COVID medications have emerged, some treatments may be helpful for improving certain symptoms regardless of the specific type of illness, such as physical rehabilitative treatments for those with shortness of breath or reduced exercise tolerance. Ensuring universal access to such specialized rehabilitative care is essential as we enter the next stage of this pandemic. So is helping patients avoid the emerging cottage industry of dodgy providers hawking unproven long-COVID therapies. Health-care professionals also need more education about the broad spectrum of COVID-19-related issues, both to improve care and reduce stigmatization of patients with all types of this illness.

    Doctors and scientists still have much to learn about symptoms that continue—or first turn up—months or weeks after an initial COVID infection. What’s clear today is that long COVID can be many different things. That may confound our efforts to categorize it and discuss its implications, but the sheer variety should not get in the way of care for all who are suffering.

    [ad_2]

    Adam Gaffney

    Source link